Red Star News Network (reporter Li Huiying) reported on April 12 that on April 12, the world's first clinical research on the treatment of periodontal disease by tooth capsule stem cells was officially launched in Chengdu, attracting many attention. This means that the clinical transformation of dental sac stem cells in the treatment of periodontitis has ushered in a breakthrough and taken a solid step towards filling the gap of stem cell drugs in China. This reporter learned today from the launching ceremony of the world's first clinical research on the treatment of periodontal disease held by the West China Stomatological Hospital of Sichuan University.
The launching ceremony was jointly sponsored by West China Stomatological Hospital of Sichuan University and Peking University Stomatological Hospital, and hosted by Chengdu Shilian Kangjian Biotechnology Co., Ltd. and Sichuan Cell Bank Co., Ltd. Wu Zhaohui, vice president of China Pharmaceutical Biotechnology Association, Zhu Songsong, vice president of West China Stomatological Hospital of Sichuan University, and relevant leaders of Sichuan Provincial Health Commission attended the launching ceremony and delivered speeches.
Professor Tian Weidong, chief expert and chief physician of West China Stomatological Hospital of Sichuan University, Luan Qingxian, director of the Department of Periodontology of Peking University Stomatological Hospital, and Guo Shujuan, professor of West China Stomatological Hospital of Sichuan University, delivered keynote speeches on the treatment of periodontal disease by dental vesicle stem cells through online + offline connections, and comprehensively interpreted and introduced the safety and efficacy of periodontal disease and dental vesicle stem cells in the treatment of periodontal bone defects.
Start clinical trials and strive to fill the gap of stem cell drugs in China
Stem cell regenerative medicine is hailed as the third medical revolution after drug therapy and surgical treatment. As the leader of the stem cell industry in Sichuan, From the beginning of its establishment, Shilian Kangjian has been committed to building a world-class high-standard cell technology and cell drug research and development and transformation application platform in Chengdu Frontier Medical Center, and the world's first allogeneic human dental vesicle stem cell preparation independently developed by it has passed the quality review and inspection of the Three Batches of the Central Inspection Institute of the State Food and Drug Administration, and has been successfully filed with the National Health Commission in 2022. At present, together with west China Stomatological Hospital of Sichuan University and Peking University Stomatological Hospital, the world's first clinical research on the treatment of periodontal disease by allogeneic dental vesicle stem cells is launched, and strives to fill the gap of stem cell drugs in China.
Wu Zhaohui, vice president of the China Association of Pharmaceutical Biotechnology, revealed at the launching ceremony through video link that since the completion of the first batch of filing projects in 2017, a total of 129 clinical research on stem cells in China have been completed and 13 projects have been completed. At present, the clinical practice of dental vesicle stem cell preparation independently developed by Shilian Kangjian is a solid step to fill the gap of stem cell drugs in China. Wu Zhaohui has high hopes for this, "Our purpose of standardizing stem cell clinical research has been initially achieved, and we hope that our institution will take this project as a starting point to further improve the management of stem cell clinical research and promote the high-quality and high-level completion of the project." ”
Stem cell therapy is at the forefront of the most promising research
Why do you care about periodontal disease? What kind of therapeutic effect can stem cells achieve? According to relevant data, in recent years, the problem of periodontal disease in the field of dentistry is particularly prominent, which is the culprit that causes tooth loss and is a common chronic disease. In addition, clinical evidence and studies have confirmed that periodontal infection may be an important infectious factor in cardiovascular and cerebrovascular diseases (atherosclerosis, myocardial infarction, stroke), diabetes, pregnancy complications, respiratory infections, rheumatoid arthritis, Alzheimer's disease and other diseases. Patients with severe periodontitis have a significantly higher incidence of the above systemic diseases, which can seriously endanger the health of the whole body. The results of the third national oral epidemiological survey in mainland China show that the prevalence of periodontitis is as high as 86.9%. The prevention and treatment of periodontal disease has become an urgent problem to be solved in the field of oral medicine.
Subverting traditional treatment, realizing periodontal soft tissue and periodontal bone regeneration to prevent tooth loss - through local transplantation of exogenous stem cells to effectively promote local tissue regeneration and repair of periodontitis, stem cell therapy has become the most cutting-edge and most promising research direction in periodontal tissue research.
Top stomatological hospitals are blessed with clinical acceleration to achieve applications
The clinical research will be carried out at the West China Stomatological Hospital of Sichuan University and the Peking University Stomatological Hospital, which shows its importance and authority. West China Stomatological Hospital, as the birthplace and cradle of modern stomatology in China, China's first stomatological specialty hospital, adhering to the modern management mode of the trinity of medical education and research, is an internationally renowned stomatology (college) hospital, and also a national clinical research center for oral diseases, and has been rated as the most popular stomatological hospital in China for many consecutive years. In the Fudan Hospital Management Rankings, it ranks first in the general ranking of Chinese hospitals, ranks first in the ranking of Chinese hospital scientific research achievements (natural index 018), and ranks first in the national hospital scientific research output rankings.
Scientific research strength is inseparable from talents. West China dental talents are abundant, chief expert Tian Weidong is the industry benchmark leader, with 38 years of clinical work experience and more than 20 years of scientific research achievements in the field of stem cells and regenerative medicine, is currently a second-level professor of Sichuan University, doctoral supervisor, national "973" and the chief scientist of key research and development program projects.
Chengdu Shilian Kangjian Biotechnology Co., Ltd. is one of the results of the transformation of the strong scientific research strength of West China Stomatological Hospital. According to reports, Shilian Kangjian Company was approved by the government of Chengdu High-tech Zone, and jointly invested by Professor Tian Weidong, the team of Professor Tian Weidong, the team of Professor Tian Weidong, the chief scientist of Chengdu Huaxi Cell Therapy Research Institute Co., Ltd. (West China Hospital), Sichuan West China Maternal and Child Health Technology Co., Ltd. (West China Second Hospital), Shanghai Pharmaceutical Group, the national "973" and the chief scientist of the key research and development program.
Tian Weidong, project leader, introduced that compared with other research projects that require whole-body infusion stem cells, clinical research on tooth capsule stem cells has higher safety, more convenient operability and more objective evaluation indicators, and is easier to be applied and promoted in future drugs and clinical treatment.
The clinical launch has also received strong support from the Sichuan Provincial Health Commission. The relevant person in charge of the Sichuan Provincial Health Commission said at the meeting that the clinical transformation of stem cells for periodontitis treatment is about to usher in a breakthrough, and scientists from the mainland will play a leading role, which is very proud. The Sichuan Provincial Health Commission attaches great importance to the filing of national stem cell projects, and has always encouraged and guided the provincial large-scale top three hospitals to actively declare, hoping that there are more stem cell projects in Sichuan for the record, and hopes that in the near future stem cell technology can solve the problems that traditional medicine cannot overcome at present, and contribute to human health. Focusing on the development strategy of Healthy China and Healthy Sichuan, we will carry out clinical research in a compliant, safe and effective manner, and look forward to bringing good news to more patients with stem cell therapy.